Han Shih Toh

China’s new five-year plan for 2026–2030 marks a decisive policy shift, placing domestic consumption and reform at the core of its growth strategy.

Beijing is encouraging A-share listed firms to list in Hong Kong, while Trump’s policies are turning some US-listed Chinese companies to also go public on HKEX. The IPO momentum is continuing with four firms listing on October 28 in the SAR.

Hong Kong-listed biotech firms are outperforming as Trump’s policies cause firms to change course from their traditional US destination, with more HKEX listings expected in the second half of 2025; experts shared their views at BIOHK.

In the long run, as China’s currency is increasingly used abroad, it will be one of the few leading global currencies, however US strength will maintain the supremacy of the US dollar, according to analysts at a Sino-German roundtable.

Chinese overseas investments, including in emerging markets, should boost the domestic economy; meanwhile, US president Donald Trump and China have extended a ‘tariff truce’ until November 10.

With geopolitical tensions rising, Beijing’s new Hong Kong–Shenzhen policy aims to open alternative capital channels

Asia's listed firms must raise their corporate governance to improve market conditions, as international investors continue to eye the US stock market, the Asian Corporate Governance Association has warned.

The games, if they go ahead, potentially in 2027, are expected to bring economic benefits to the Greater Bay Area, including Hong Kong, and countries part of the Belt and Road Initiative.

Analysts are betting that US president Donald Trump and his Chinese counterpart Xi Jinping will strike a deal, which would spur US players to buy Chinese stocks, just as overall sentiment for mainland China and Hong Kong improves.

Rmb internationalisation faces challenges from Trump’s determination to keep the US dollar as the leading global currency; FA understands that Hong Kong is taking a more "commercial" approach.